Overview

A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Status:
Completed

Trial end date:
2019-01-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate the efficacy and safety of Certolizumab Pegol (CZP) in the treatment of moderate to severe chronic plaque Psoriasis (PSO) in Japanese subjects.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

UCB Biopharma S.P.R.L.

Treatments:

Certolizumab Pegol